Page 95 of 291 · 8,722 total

patent terminated or settled · Mar 28, 2025

Henri Daussi, LLC v.ECNA, LLC et al.

· IPR2025-00807

Henri Daussi, LLC and ECNA, LLC filed a joint motion to terminate IPR2025-00807 after reaching a settlement, ending the Board proceeding without a final written decision.

patent · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00794

The Director denied Intel’s request for rehearing of the discretionary denial and institution decision in IPR2025-00794, leaving the patent challenge uninstated.

patent terminated or settled · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00795

NVIDIA and Advanced Cluster Systems settled their dispute over U.S. Patent 8,676,877 B2 and jointly moved to terminate the inter partes review. The PTAB granted the motion, ending the proceeding without a merits decision.

patent terminated or settled · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00794

NVIDIA and Advanced Cluster Systems settled their dispute, leading the PTAB to terminate the inter partes review of patent 8,140,612 B2.

patent terminated or settled · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00794

NVIDIA and Advanced Cluster Systems jointly moved to terminate IPR2020-01608 concerning patent 8,082,289 B2 after the Board had instituted the review. The Board granted the motion, ending the proceeding without a final written decision.

patent · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00795

The USPTO denied Intel’s request for rehearing of the Director’s discretionary denial and the denial of institution in IPR2025‑00795, leaving the original decision intact.

patent · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

An email from the PTAB Director informs the parties that Director Review requests have been received for IPR2025-00682 and IPR2025-00683, outlining a 15‑page, five‑day response window and prohibiting new evidence.

patent terminated or settled · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00795

NVIDIA and Advanced Cluster Systems settled their dispute over U.S. Patent No. 8,140,612 B2, leading to a joint motion that terminated the inter partes review after it had been instituted.

patent · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

Advanced Integrated Circuit Process LLC submits an authorized response urging the Director to deny Taiwan Semiconductor Manufacturing Company's request for Director Review of a discretionary denial to institute an IPR on patent 8,198,686. The response rebuts the petitioner’s arguments on national security, settled expectations, duplication, and examiner error.

patent denied · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

The USPTO denied Taiwan Semiconductor Manufacturing Company's request for Director Review of the institution denial in IPR2025-00682, leaving the earlier decision intact.

patent · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

TSMC seeks a Director Review to overturn a discretionary denial and have the PTAB evaluate the validity of its ‘686 semiconductor patent, citing national‑security stakes and examiner errors. The request stresses long‑standing settled expectations and a lack of prior enforcement.

patent · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

Court decision.

patent · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

Court decision.

patent · Mar 28, 2025

Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.

· PGR2025-00039

Merck has filed a Post‑Grant Review petition challenging Halozyme’s U.S. Patent 12,104,185 covering modified PH20 hyaluronidase proteins. The petition argues the claims are overly broad, lack written description and enablement, and are obvious in view of prior art. The case is pending institution.

patent · Mar 28, 2025

Samsung Electronics Co., Ltd. et al. v.GenghisComm Holdings, LLC

· IPR2025-00781

Samsung has filed an IPR petition challenging 13 claims of GenghisComm’s OFDM patent, alleging anticipation and obviousness over Galda, Dowling, Kaiser and Bury. The petition also argues the patent’s priority chain is broken and that discretionary denial is unwarranted.

patent · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00795

Intel has filed an IPR petition seeking to invalidate claims 26‑29 and 35‑39 of U.S. Patent 10,333,768, arguing they are obvious over prior‑art papers (Menon, Trefethen) combined with IBM documentation and the MPI standard. The petition also challenges discretionary denial under §§ 314(a) and 325(d).

patent · Mar 28, 2025

Intel Corporation v.Advanced Cluster Systems, Inc.

· IPR2025-00794

Intel has filed an IPR petition seeking to invalidate 30 claims of Advanced Cluster Systems’ ’768 patent covering cluster‑computing architectures, arguing that the invention was disclosed years earlier in Cornell’s MultiMATLAB papers and IBM documentation.

patent · Mar 28, 2025

Taiwan Semiconductor Manufacturing Company Limited v.Advanced Integrated Circuit Process LLC

· IPR2025-00682

TSMC has filed an IPR petition seeking to invalidate 35 claims of the ’686 semiconductor device patent owned by Advanced Integrated Circuit Process. The petition alleges examiner error and that multiple prior‑art references render the claims anticipated or obvious.

patent · Mar 28, 2025

GE Healthcare Ltd. et al. v.The Johns Hopkins University et al.

· IPR2025-00808

GE Healthcare petitions the PTAB to invalidate three claims of a Johns Hopkins FAP‑targeting radiopharmaceutical patent, asserting obviousness over US‑633, US‑121, Meletta and Jansen references.

patent · Mar 28, 2025

Walmart Inc. et al. v.RavenWhite Security, Inc. et al.

· IPR2025-00810

Walmart has filed an IPR petition seeking cancellation of all ten claims of RavenWhite’s ’823 patent, asserting obviousness over two prior‑art references (Hinton and Varghese) and a lack of written‑description support.

patent · Mar 28, 2025

Walmart Inc. et al. v.Security Technology, LLC et al.

· IPR2025-00809

Walmart has filed an IPR petition seeking cancellation of all 19 claims of Security Technology’s ’402 patent, alleging obviousness over multiple prior‑art references. The petition presents two grounds, each covering claims 1‑19, and argues that discretionary denial is not warranted.

patent · Mar 28, 2025

Henri Daussi, LLC v.ECNA, LLC et al.

· IPR2025-00807

Henri Daussi, LLC petitions the PTAB to invalidate 14 claims of U.S. Patent 9,398,791 covering an oblong diamond cut, citing multiple prior‑art references for lack of novelty and obviousness.

patent · Mar 28, 2025

Samsung Electronics Co., Ltd. et al. v.GenghisComm Holdings, LLC

· IPR2025-00780

Samsung has filed an IPR petition challenging 14 claims of GenghisComm’s ’842 OFDM patent, asserting anticipation and obviousness over multiple prior‑art references. The petition argues that discretionary denial is unwarranted and that Fintiv factors favor institution.

patent · Mar 28, 2025

Liberty Energy Inc. et al. v.U.S. Well Services, LLC et al.

· IPR2025-00778

Liberty Energy petitions the PTAB to institute an IPR against U.S. Well Services' 11,959,533 patent covering multi‑plunger hydraulic fracturing pumps. The petition asserts that all 25 claims are obvious under §103, relying on a series of prior‑art combinations and argues that institution is proper under the Fintiv and Becton factors.

patent instituted · Mar 28, 2025

Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.

· PGR2025-00039

Merck Sharp & Dohme successfully challenged Halozyme's patent claims in a PGR proceeding, focusing on enablement and obviousness. The Board adopted a functional claim construction requiring 'modified PH20 polypeptide' to exhibit hyaluronidase activity.

patent terminated or settled · Mar 27, 2025

USAA Federal Savings Bank v.PACid Technologies, LLC

· IPR2025-00755

USAA Federal Savings Bank and PACid Technologies settled their dispute over U.S. Patent 11,070,530, leading to a joint motion that terminated the IPR proceeding before it was instituted.

patent terminated or settled · Mar 27, 2025

USAA Federal Savings Bank v.PACid Technologies, LLC

· IPR2025-00755

USAA Federal Savings Bank and PACid Technologies have jointly moved to terminate IPR2025-00755 after resolving their dispute in district court, invoking 35 U.S.C. § 317(a).

patent terminated or settled · Mar 27, 2025

USAA Federal Savings Bank v.PACid Technologies, LLC

· IPR2025-00752

USAA Federal Savings Bank and PACid Technologies have resolved their dispute over U.S. Patent No. 10,044,689 and jointly moved to terminate the inter partes review. The district‑court case involving the same patent was also dismissed.

patent terminated or settled · Mar 27, 2025

USAA Federal Savings Bank v.PACid Technologies, LLC

· IPR2025-00752

USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, resulting in a Board‑ordered termination of IPR2025-00752 covering patent 10,044,689.

patent terminated or settled · Mar 27, 2025

Alpinestars S.p.A et al. v.Dainese S.p.A.

· IPR2025-00750

Alpinestars and Dainese have executed a settlement that ends all pending cross‑border patent disputes over airbag technology for motorcyclists. The agreement includes dismissal of lawsuits, withdrawal of oppositions, and a mutual non‑challenge pledge.

1 •••949596•••291
Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →